Hanny Al-Samkari, MD, Massachusetts General Hospital, Boston, MA, highlights exciting developments in treatments for patients with chronic immune thrombocytopenia (ITP), including efgartigimod, rilzabrutinib, mezagitamab, and TAK-079. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Novel promising agents for the treatment of ITP
Теги
Speaker: Hanny Al-SamkariInstitution: Massachusetts General HospitalEvent: ASH 2022Format: InterviewSubject: Immune ThrombocytopeniaSubject: Rare DiseasesField: TreatmentField: Immuno-OncologyField: Trial UpdatesMedicines: EfgartigimodMedicines: IptacopanMedicines: RilzabrutinibMedicines: MezagitamabMedicines: AntibodiesBTK inhibitorcomplementplasma cellsMedicines: TAK-079Subject: Non-Malignant